Want to see JP:4584 full AI Analyst Report?
Top Page
Kidswell Bio Corporation
(4584)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥166.00
▼(-18.23% Downside)
Action:Upgraded
Date:08/21/26
The score is held down primarily by weak financial quality—volatile profitability, elevated leverage, and a return to significant cash burn in the most recent year. Technicals provide some offset via improving short-term momentum, but extended oscillators and a still-weak longer-term trend limit that support, while valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Commercial scale-up
The substantial multi-year revenue increase indicates that Kidswell Bio has expanded commercial traction and market reach. A larger revenue base can improve operating leverage over time if the company can stabilize margins and control development and selling costs.
Negative Factors
Elevated leverage
Leverage remains high for a company with inconsistent profitability, increasing refinancing and interest-burden risk. Debt reduces financial flexibility when operating results weaken and may constrain investment in biologic development, commercialization, or other growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial scale-up
The substantial multi-year revenue increase indicates that Kidswell Bio has expanded commercial traction and market reach. A larger revenue base can improve operating leverage over time if the company can stabilize margins and control development and selling costs.
Read all positive factors
Kidswell Bio Corporation (4584) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.05B
Dividend YieldN/A
Average Volume (3M)766.13K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-2.86%
EPS Growth-210.09%
CountryJP
Employees32
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.31
Shares Outstanding50,582,990
10 Day Avg. Volume871,200
30 Day Avg. Volume766,126
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.17
Price to Sales (P/S)1.80
P/FCF Ratio-10.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)19.3
Revenue Forecast (FY)¥4.92B
Kidswell Bio Corporation Business Overview & Revenue Model
Company Description
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebrandin...
How the Company Makes Money
null...
Kidswell Bio Corporation Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
38
Negative
Cash Flow
32
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.59B | 5.08B | 2.43B | 2.78B | 1.57B |
| Gross Profit | 1.75B | 1.64B | 1.04B | 1.53B | 1.02B |
| EBITDA | -138.26M | 116.26M | -1.38B | -620.45M | -531.89M |
| Net Income | -413.99M | -21.14M | -1.42B | -657.43M | -550.86M |
Balance Sheet | |||||
| Total Assets | 6.09B | 7.01B | 5.09B | 3.89B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 3.29B | 3.00B | 2.23B | 1.07B | 1.16B |
| Total Debt | 2.55B | 1.84B | 2.58B | 1.95B | 700.00M |
| Total Liabilities | 4.43B | 5.60B | 4.25B | 2.66B | 1.77B |
| Stockholders Equity | 1.65B | 1.41B | 831.47M | 1.23B | 1.70B |
Cash Flow | |||||
| Free Cash Flow | -1.11B | 930.26M | -453.63M | -1.42B | -1.17B |
| Operating Cash Flow | -1.09B | 936.71M | -453.63M | -1.42B | -1.17B |
| Investing Cash Flow | -12.62M | 65.08M | 0.00 | -28.82M | 526.51M |
| Financing Cash Flow | 1.40B | -240.06M | 1.62B | 1.36B | 369.08M |
Kidswell Bio Corporation Technical Analysis
Positive
203.00
Price Trends
149.08
Positive
176.96
Positive
210.35
Negative
Market Momentum
7.55
Negative
71.72
Negative
87.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4584, the sentiment is Positive. The current price of 203 is above the 20-day moving average (MA) of 157.10, above the 50-day MA of 149.08, and below the 200-day MA of 210.35, indicating a neutral trend. The MACD of 7.55 indicates Negative momentum. The RSI at 71.72 is Negative, neither overbought nor oversold. The STOCH value of 87.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4584.
Kidswell Bio Corporation Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥35.78B | -80.07 | ― | ― | 3.43% | -53.59% | |
51 Neutral | ¥22.13B | -11.71 | ― | ― | ― | 6.10% | |
47 Neutral | ¥37.40B | 56.85 | ― | ― | -47.32% | ― | |
45 Neutral | ¥9.05B | -23.68 | ― | ― | -2.86% | -210.09% | |
45 Neutral | ¥14.94B | -32.46 | ― | ― | -18.71% | -246.54% | |
42 Neutral | ¥9.19B | -8.01 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4584
Kidswell Bio Corporation
180.00
-62.00
-25.62%
JP:4593
Healios KK
282.00
-208.00
-42.45%
JP:4599
StemRIM Inc.
351.00
46.00
15.08%
JP:4978
ReproCELL Inc.
149.00
-29.00
-16.29%
JP:7774
Japan Tissue Engineering Co., Ltd.
868.00
384.00
79.34%
JP:7776
CellSeed Inc.
234.00
-207.00
-46.94%
Kidswell Bio Corporation Corporate Events
Kidswell Bio Balances Biosimilar Margin Gains With High-Growth Cell Therapy Push in FY2026 Q1
Aug 13, 2026
Kidswell Bio reported fiscal 2026 first-quarter consolidated net sales of ¥1.27 billion, down year on year as lower delivery volumes for some biosimilars offset steady manufacturing progress, while gross profit of ¥431 million and operat...
Kidswell Bio Boosts Q1 Profit Despite Lower Sales, Keeps Guidance Range Wide
Aug 13, 2026
Kidswell Bio reported consolidated net sales of ¥1.27 billion for the first quarter ended June 30, 2026, down 26.2% year on year, but improved profitability with operating income rising 17.3% to ¥216 million and net income attributable t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.